Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
KemNet
AddedMar 20, 2024
UpdatedJul 3, 2026
KemNet

KemNet

Seed

KemNet: Premium, fast-acting pharmaceuticals for specific health needs.

HQ
Edmonton, Alberta, CA
Founded
2022
Accelerator
Y Combinator logoY CombinatorS22
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to enhance patient care through innovative drug reformulations, KemNet focuses on providing pharmacies with premium pharmaceuticals tailored for specific health needs. Their core vision is to improve the efficacy and delivery of popular medications, ensuring they meet the unique requirements of various patient groups. KemNet's product line includes reformulated drugs for erectile dysfunction, hair growth, pain management, weight loss, and women's health, all designed to act faster and more effectively than standard alternatives.

KemNet has garnered trust from over 30 pharmacies that rely on their advanced formulations. Notable achievements include the development of erectile dysfunction medications that work up to eight times faster than existing options. Through these innovations, KemNet has significantly impacted patient outcomes by offering more efficient and targeted treatments. Their commitment to pharmaceutical excellence continues to drive their influence in the healthcare market.

KemNet - Quick Facts

When was KemNet founded?

KemNet was founded in 2022.

Where is KemNet's headquarters located?

KemNet's headquarters is located in Edmonton, Alberta, CA.

When was KemNet's last funding round?

KemNet's most recent funding round was for $500k (USD) in August 2022.

How much has KemNet raised to-date?

As of Aug 22, 2022, KemNet has raised a total of $500k (USD).

How many employees does KemNet have?

KemNet has 2 employees as of Aug 23, 2023.

KemNet - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Canada
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Distribution
  • Healthtech
  • SaaS
NAICS
  • 456000Health and Personal Care Retailers
  • 450000Retail Trade
  • 456100Health and Personal Care Retailers
  • 456110Pharmacies and Drug Retailers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 3 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 5900Miscellaneous Retail
  • 5910Drug Stores And Proprietary Stores